WO2004069156A3
(en )
2004-09-23
Inactivated probiotic bacteria and methods of use thereof
EP1296693A4
(en )
2005-05-25
Immunotherapy or treating bacterial or viral infection at mucosal surfaces with probiotics, and compositions therefor.
MY129263A
(en )
2007-03-30
Vaccine composition
PL351893A1
(en )
2003-06-30
Vaccines
TR200202194T2
(en )
2003-01-21
Polyglutamic acid-camptothecin compounds and preparation methods
AU2002342091A1
(en )
2003-06-30
Silicone priming compositions, articles and methods_____________
WO2003063899A3
(en )
2003-12-04
Vaccine adjuvant based on a cd4 0 ligand
WO2002036790A3
(en )
2003-01-23
Influenza virus vector for infection of dendritic cells
WO2004075829A3
(en )
2005-03-24
Adjuvanted influenza vaccine
WO2007030810A3
(en )
2007-07-12
Multiparameter whole blood monitor and method
AU2002338832A1
(en )
2003-04-14
Vaccine
MXPA02007478A
(en )
2004-08-23
Human immunodeficiency virus vaccine.
GB2386072A
(en )
2003-09-10
Novel vaccine
AU2001292610A1
(en )
2002-03-22
Genetically engineered co-expression dna vaccines, construction methods and uses thereof
MY144492A
(en )
2011-09-30
Human papillomavirus vaccine comprising hpv 16 and hpv 18 virus like particles, which induce cross protection against other hpv types
WO2003051288A3
(en )
2003-11-27
Mycobacterial vaccine
WO2001055111A8
(en )
2001-09-07
Biaryl compounds, their preparation and their use in therapy
WO2004091524A3
(en )
2009-04-16
Respiratory virus vaccines
AU2003271215A8
(en )
2004-05-04
Vector for anti-hpv vaccine and transformed microorganism by the vector
GB2376687B
(en )
2004-06-09
Herpes viruses for immune modulation
WO2003053338A3
(en )
2003-11-27
Novel chimeric rev, tat, and nef antigens
UA67251A
(en )
2004-06-15
Strain paramixovirus-3 bovis "zksm" for the preparation of vaccines and diagnosticums
UA67250A
(en )
2004-06-15
Strain bovinae herpesvirus-1 "moldavian" for the preparation of vaccines and diagnosticums
AU2002320079A1
(en )
2002-12-23
Vaccines, immunotherapeutics and methods of using the same
AU2002342949A1
(en )
2003-06-19
Vaccine composition comprising at least two valences, one with enhanced adjuvant and not the other